Core growth and cash strengthen; outlook is largely a recast.

The quarter’s operating trend improved, but the headline comparison is distorted by the portfolio change. Continuing-operations sales rose 2% reported and 6% on a comparable currency-neutral basis, while adjusted operating EBITDA rose to $408 million and adjusted EPS excluding acquisition-intangible amortization increased to $0.82 from $0.77. Every remaining segment posted currency-neutral sales growth, led by Scent at 8%. (Financial Highlights; Q2 Segment Results; Adjusted EPS ex. Amortization)

This is not a clean EPS beat-or-miss against the published estimate. The published Q2 EPS consensus of roughly $1.07–$1.12 and revenue expectation near $2.7 billion were formed before Food Ingredients was shifted to discontinued operations. IFF now reports $0.82 of continuing-operations adjusted EPS ex amortization and $1.95 billion of continuing sales, while total quarterly sales including the discontinued business were $2.78 billion. That means the revenue base was broadly intact versus the old expectation, but the filing does not provide an apples-to-apples total-company adjusted EPS figure to substantiate either a beat or a miss.

Guidance is mostly a presentation reset rather than a lower underlying outlook. Adding the company’s approximately $3.2 billion discontinued-sales estimate to the new $7.4 billion–$7.6 billion continuing-sales range implies about $10.6 billion–$10.8 billion of total 2026 sales. Similarly, the new $1.53 billion–$1.60 billion continuing EBITDA range plus roughly $520 million from discontinued operations implies about $2.05 billion–$2.12 billion. Management says the outlook for the three continuing businesses is unchanged; the real nuance is that the implied combined EBITDA ceiling is modestly below the prior $2.15 billion top end, rather than an outright operational guide raise. (Financial Guidance)

The genuinely new positive is capital allocation, though it depends on closing the sale. IFF specified that more than $1 billion of Food Ingredients proceeds will go to debt reduction and authorized a $2.5 billion repurchase program, beginning with a $500 million accelerated repurchase in the second half of 2026; the remaining $2.0 billion is expected only after the Food Ingredients transaction closes, targeted by the end of the second quarter of 2027. The divestiture itself was already public, so this filing adds clarity on proceeds rather than a new sale outcome. (Food Ingredients Divestiture; Share Repurchase Authorization)

The cleaner portfolio still carries execution costs and a meaningful legal overhang. GAAP continuing EPS was only $0.13, versus $2.14 a year ago, because reported results absorbed $71 million of regulatory costs, a $27 million loss on assets classified as held for sale, and other transformation-related items; the prior year also benefited from a $488 million debt-extinguishment gain and unusual tax items. Separately, management estimates about $100 million of stranded corporate costs from the Food Ingredients sale, with roughly two-thirds targeted for removal in the first year after closing and substantially all within two years. So the core improvement is real, but the economic payoff from simplification remains dependent on cost-removal and transaction execution. (Income Statement; Reconciliation of Net Income and EPS; Food Ingredients Divestiture)